Valuation: AstraZeneca PLC

Market Cap 299B 262B 240B 224B 425B 28,504B 431B 2,888B 1,122B 13,998B 1,124B 1,100B 48,306B P/E 2026 *
24.1x
P/E 2027 * 21.2x
Enterprise Value 319B 279B 256B 239B 452B 30,338B 459B 3,073B 1,195B 14,899B 1,196B 1,170B 51,415B EV / Sales 2026 *
5.03x
EV / Sales 2027 * 4.65x
Free-Float
96.63%
Yield 2026 *
1.73%
Yield 2027 * 1.82%
1 day+2.98%
1 week+3.70%
Current month+3.64%
1 month+12.14%
3 months-3.99%
6 months+7.35%
Current year+7.08%
1 week 160.85
Extreme 160.85
170.35
1 month 151.1
Extreme 151.1
170.35
Current year 148
Extreme 148
180.45
1 year 117.7
Extreme 117.7
180.45
3 years 112.45
Extreme 112.45
180.45
5 years 94
Extreme 94
180.45
10 years 47.74
Extreme 47.74
180.45
Manager TitleAgeSince
Chief Executive Officer 66 2012-09-30
Director of Finance/CFO 52 2021-07-31
Compliance Officer - 2022-12-31
Director TitleAgeSince
Director/Board Member 70 1999-04-05
Director/Board Member 66 2012-09-30
Director/Board Member 65 2017-04-26
Change 5-day change 1-year change 3-year change Capi.($)
+2.98%+3.70% - - 301B
+1.86%+7.65%+55.77%+158.84% 1,082B
+3.57%+7.42%+69.09%+58.92% 633B
+3.99%+7.37%+36.87%+93.77% 461B
+3.86%+1.85%+31.30%+24.86% 339B
-0.08%+1.52%+29.96%+42.13% 292B
-1.54%+3.56%-25.96%-40.53% 225B
+3.55%+6.05%+26.04%+68.52% 202B
+4.21%+6.00%+17.72%+70.33% 163B
+1.84%+2.75%-3.95%-33.70% 139B
Average +2.42%+4.47%+26.32%+49.24% 393B
Weighted average by Cap. +2.50%+5.48%+40.22%+80.51%

Financials

2026 *2027 *
Net sales 63.33B 55.39B 50.83B 47.45B 89.91B 6,029B 91.25B 611B 237B 2,961B 238B 233B 10,217B 66.98B 58.58B 53.76B 50.19B 95.1B 6,376B 96.51B 646B 251B 3,131B 251B 246B 10,806B
Net income 12.46B 10.9B 10B 9.34B 17.7B 1,187B 17.96B 120B 46.72B 583B 46.8B 45.78B 2,011B 13.97B 12.22B 11.21B 10.47B 19.83B 1,330B 20.13B 135B 52.36B 653B 52.44B 51.3B 2,254B
Net Debt 19.27B 16.86B 15.47B 14.44B 27.36B 1,835B 27.77B 186B 72.24B 901B 72.36B 70.78B 3,109B 12.07B 10.56B 9.69B 9.04B 17.14B 1,149B 17.39B 116B 45.25B 564B 45.32B 44.33B 1,947B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
26-07-03 €169.50 +2.98% 353
26-07-02 €164.60 -0.15% 350
26-07-01 €164.85 +0.79% 182
26-06-30 €163.55 -1.33% 289
26-06-29 €165.75 +2.13% 895
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
193.04USD
Average target price
217.82USD
Spread / Average Target
+12.83%

Quarterly revenue - Rate of surprise